Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-04
2006-07-04
Jones, Dwayne (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07071206
ABSTRACT:
Compounds and methods of using these compounds to treat neurodegenerative diseases, especially Alzheimer's disease, are provided. The compounds that are provided for the treatment of neurodegenerative diseases can be represented by a general formula (I):wherein R1is Me, Et or PhCH2; R2is H, PhCH2or 6-Me-3-Py-(CH2)2; and R3is H, Me or Br. The solid line accompanied by the dotted line i.e.represents a single or double bond and salts thereof with pharmacologically acceptable acids and quaternary derivatives.
REFERENCES:
patent: 3718657 (1973-02-01), Garmaise et al.
patent: 3743740 (1973-07-01), Barkov et al.
patent: 3991199 (1976-11-01), Berger
patent: 4636563 (1987-01-01), Abou-Gharbia
patent: 4985256 (1991-01-01), Glick
patent: 5319096 (1994-06-01), Kosley et al.
patent: 5958919 (1999-09-01), Olney et al.
patent: RE36397 (1999-11-01), Zhang et al.
patent: 6017957 (2000-01-01), Skolnick et al.
patent: 6187785 (2001-02-01), Zefirov et al.
patent: 6362160 (2002-03-01), Dawson et al.
patent: 6391871 (2002-05-01), Olney et al.
patent: 6930112 (2005-08-01), Weaver et al.
patent: 2001/0020028 (2001-09-01), Zefirov et al.
patent: 2002/0102597 (2002-08-01), Bitler et al.
patent: 2002/0115682 (2002-08-01), Zefirov et al.
patent: 2002/0197233 (2002-12-01), Relton et al.
patent: 2004/0044022 (2004-03-01), Zefirov, Jr. et al.
patent: 2 117 755 (1993-10-01), None
patent: 1952800 (1969-10-01), None
patent: 1813229 (1970-08-01), None
patent: 0 230 370 (1987-07-01), None
patent: 0 230 370 (1987-07-01), None
patent: 0 230 370 (1987-07-01), None
patent: 0 424 179 (1991-04-01), None
patent: 0 424 179 (1991-04-01), None
patent: 0 581 456 (1994-02-01), None
patent: 1245155 (1971-09-01), None
patent: 1276113 (1972-06-01), None
patent: 1450002 (1976-09-01), None
patent: 1586655 (1981-03-01), None
patent: 9-216882 (1997-08-01), None
patent: 2 106 864 (1998-03-01), None
patent: 2 140 417 (1999-10-01), None
patent: 1138164 (1985-02-01), None
patent: 1803108 (1993-03-01), None
patent: 1816451 (1993-05-01), None
patent: WO-94/06428 (1994-03-01), None
patent: WO-97/15225 (1997-05-01), None
patent: WO-2005/055951 (2005-06-01), None
Enlglish Language Equivalent Abstract of SU 873883, which is GB 1,586,655.
Enlglish Language Equivalent Abstract of SU 592359, which is GB 1,450,002.
Enlglish Language Equivalent Abstract of SU 665804, which is US 3,991,199.
Abou-Gharbia, M. et al. (1987). “Antipsychotic Activity of Substituted y-Carbolines,”J. Med. Chem.30:1818-1823.
Avdulov, N.A. et al. (1985). “Interaction of Psychotropic Preparations with Model Lipid Membranes,”Bulletin of Experimental Biology and Medicine100(10):440-442. (English Translation, 4 pages.).
Baker, G.T. (Jan.-Apr. 1993). “Effects of Various Antioxidants on Aging inDrosophila,” Toxicol. Ind. Health9(1/2):163-186.
Benes, L. (1986). “Free Radicals and Ischemic States,”Ceskoslovenska Farmacie35(5):230-232. (English Translation, 5 pages.).
Benes, L. (Jun. 1986). “Free Radicals and Ischemic States,”The Czechoslovak Pharmcy Journal35(5):230-232. (Alternative English Translation, 5 pages.).
Bukatina, Y.Y. et al. (1992). “Scale For Evaluating the Mental Condition of Elderly Dementia Patients,”Social and Clinical Psychiatry2(4):29-37. (English Translation, 10 pgs.).
Buu-Hot, N.P. et al. (1964). “Carcinogenic Nitrogen Compounds. Part XXXIX. A New Synthesis of y-Carbolines and 2,10-Diaza-anthracenes,”J. Chem. Soc. 2:708-711.
Cattanach, C.J. et al. (1968). “Studies in the Indole Series. Part IV. Tetrahydro-1H-pyrido[4,3-b]-indoles as Serotonin Antagonists,”J. Chem. Soc.C:1235-1243.
Collingridge, G.L. et al. (1994).The NMDA ReceptorSecond Edition, Oxford University Press: New York, NY, 4 pages (Table of Contents Only.).
Comfort, A. et al. (Jan. 22, 1971). “Effect of Ethoxyquin on the Longevity of C3H Mice,”Nature229(5282):254-255.
Disterhoft, J.F. et al. eds. (Dec. 15, 1994). “Calcium Hypothesis of Aging and Dementia,”Ann. N.Y. Acad. Sci.vol. 747, 6 pages. (Table of Contents Only.).
Evans, R.H. et al. (Jan. 1982). “The Effects of a Series of ω-Phosphonic α-Carboxylic Amino Acids on Electrically Evoked and Excitant Amino Acid-Induced Responses in Isolated Spinal Cord Preparations,”Brit. J. Pharmacol. 75:65-75.
Frolkis, V.V. et al. (1991).Life Span Prolongation, Translated from Russian by Edelsburg, N.G., CRC Press: Boca Raton, FL, 9 pages, including Table of Contents.
Gankina, Y.M. et al. (1992). “Effect of Certain Antihistamine Preparations on3H-Mepyramine and3H-Cimetidine Binding to Histamine Receptors in the Rat Brain,”Chemical and Pharmaceutical Journal26(5):9-12. (English Translation, 5 pages.).
Gankina, Y.M. et al. (1993). “Effect of Antihistamine Preparations on Labeled Mepyramine, Ketanserin, and Quinuclidinyl Benzilate Binding in the Rat Brain,”Experimental and Clinical Pharmacology56(1):22-24. (English Translation, 5 pages.).
Geerts, H. et al. (2003). “Galantamine Benefits in Alzheimer's Disease are Related to Increases in Dopamine Output,”Abstracts of the IX International Congress on Schizophrenia Research, Colorado Springs, CO, Mar. 29-Apr. 2, 2003, 60(1):135.
Gill, R. et al. (1987). “High-Performance Liquid Chromatographic System for the Separation of Tricyclic Antidepressant and Related Drugs Using ODS-Hypersil,”Journal of Chromatography391(2):461-464.
Grigoryev, V.V. (1993). “Effects of NMDA and Quinolinic Acid on Rat Cerebral Cortex Neurons,”Reports From the Academy of Sciences330(5):646-648. (English Translation, 4 pgs.)
Grigoryev, V.V. et al. (1988). “Anticonvulsant Activity of Glutamate Receptor Antagonists in the Phosphorus-Containing Aminocarboxylic-Acid Series,”J. of Chem. and Pharm.22(3):275-277. (English Translation, 3 pgs.).
Harbert, C.A. et al. (1980). “Neuroleptic Activity of the 5-Aryltetrahydro-y-carboline Series,”Mol. Pharm.17(1):38-42.
Heller, W.M. et al. eds. (1989).USAN and the USP Dictionary of Drug Names: USAN 1990: 1961-1989 Cumulative List, U.S. Pharmacopeial Convention, Inc.: Rockville, MD, 26th edition, p. 196.
Hörtein, U. (1954). “On Knowledge of the Tetrahydrocarboline Compounds (Communication I),”Chem. Ber.87(4):463-472. (English Translation, 13 pgs.).
Kittová, M. et al. (Nov. 1985). “Antiarrhythmic and Hemodynamic Effects of a Pyridoindole Derivative (DH 1011) on Experimental Models of Heart Rhythm and Function Disorders,”Bratisl Lek. Listy.84(5):542-556. (English Translation, 15 pages.).
Klyuyev, M.A. ed. (1991).Handbook: Medicinal Agents Used in Medical Practice in the USSRMeditsina Publishing House: Moscow, USSR, p. 512. (English Translation, 2 pgs.).
Koh, J-Y. et al. (1990). “β-Amyloid Protein Increases the Vulnerability of Cultured Cortical Neurons to Excitotoxic Damage,”Brain Res.533:315-320.
Kost, A.N. et al. (1973). “Indole Chemistry: XXXIII. On NH Group Pyridylethylation in Indole Compounds,”Heterocyclic Compound Chemistry2:207-212. (English Translation, 6 pgs.).
Kucherova, N.F. et al. (1956). “Indole Derivatives. II. Synthesis of Certain 1,2,3,4-Tetrahydro-y-Carboline Derivatives,”J. of General Chemistry26(88):3149-3154. (English Translation, 6 pages.).
Lal, H. et al. eds. (1989).Excitatory Amino Acids and Drug Research, Alan R. Liss, Inc.: New York, NY, 17(4):380.
Litchfield, J.T. Jr. et al. (1949). “A Simplified Method of Evaluating Dose-Effect Experiments,”J. Pharmacol. Exp. Therap.96:99-113.
Maragos, W.F. et al. (Mar. 9, 1987). “Loss of Hippocampal [3H]TCP Binding in Alzheimer's Disease,”Neurosci. Lett.74(3):371-376.
Mashkovskiy, M.D. (1993).Drugs:(A Manual for Physicians), Meditsina Publishing House: Moscow, USSR, 12th Edition, 1:383. (English Translation, 4 pages.).
Mattson, M.P. (Jan. 1990). “Antigenic Changes Similar to Those Seen in Neurofibrillary Tangles are Elicited by Glutamate and Ca2+Influx in Cultured Hippocampal Ne
Afanasiev Andrei Z.
Afanasieva Svetlana V.
Bachurin Sergei O.
Bukatina Elizaveta E.
Chetverikov Valery P.
Jones Dwayne
Medivation, Inc.
Morrison & Foerster / LLP
LandOfFree
Agents for treating neurodegenerative disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Agents for treating neurodegenerative disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agents for treating neurodegenerative disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3529191